

## Department of Cancer Pathology

copy No.

Date:

## Examination: Histopathological examination

Internal invoice No.

Cost of diagnostic procedure

Examination No.:

Patient: XXX

PESEL: XXX

Age:

Gender: F

**Material: Total organ resection – left breast with axillary tissues**

Unit in charge:

Physician in charge:

Material collected on:

Material received on:

Expected time of examination: up to 8 working days

Clinical diagnosis: Cancer of the left breast.

1CD-0-3

carcinoma, infiltrating duct, nos 8500/3  
Site: breast, nos C50.9

JW 4/12/11

Examination performed on:

Results of immunohistochemical examination:

Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell nuclei. HER2 protein stained with HercepTest™ by DAKO. Score = 2+, FISH verification recommended.

Compliance validated by: .

Examination performed on: :

Macroscopic description:

Left breast sized 22 x 15 x 5 cm removed along with axillary tissues sized 13 x 7.5 x 1.5 cm and a skin flap of 19 x 11 cm.

Retracted nipple. Tumour sized 2.5 x 2 x 2.8 cm found on the boundary of lower quadrants, located 3.5 cm from the lower boundary, 0.4 cm from the base and 3 cm from the skin.

Microscopic description:

Carcinoma ductale invasivum - NHG2 (2+2+3/21 mitoses/10 HPF - visual area 0.57mm). Glandular tissue showing lesions of the type mastopathia fibrosa et cystica, hyperplasia ductalis simplex (UDH).

**AXILLARY LYMPH NODES:**

Metastases carcinomatose in lymphonodis (No III/XXIII).

Infiltratio capsulae lymphonodorum.

Histopathological diagnosis:

Carcinoma ductale invasivum mammae sinistre.

Invasive ductal carcinoma of the left breast.

Metastases carcinomatose in lymphonodosi axillae (No III/XXIII) (NHG2, pT2, pN1a).

Cancer metastases of axillary lymph nodes (No III/XXIII) (NHG2, pT2, pN1a).

Compliance validated by: :

Examination performed on:

UUID:E69CF3E3-4799-4892-87E9-4291B14A1B9C  
TCGA-D8-A1X9-01A-PR

Redacted



Criteria	Yes	No
Diagnosis Discrepancy	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Primary Tumor Site Discrepancy	<input checked="" type="checkbox"/>	<input type="checkbox"/>
HIPAA Discrepancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Prior Malignancy History	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Dual/Synchronous Primary Noted	<input type="checkbox"/>	<input checked="" type="checkbox"/>
Carries circle:	QUALIFIED	DISQUALIFIED
Reviewed by:	Date Reviewed: JW 4/12/11	

**Examination: Histopathological examination**

page 2 / 2

Examination No.:

Patient: XXX

PESEL: XXX

Gender: F

---

Examination performed on:

Results of immunohistochemical examination:

**RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by Path Vysion HER2 DNA Probe Kit**

**FINAL RESULT:**

**HER-2 GENE AMPLIFICATION NOT FOUND**

---

Compliance validated by:

**CONTACT YOUR DOCTOR WITH THIS REPORT!**